@MichaelKrey tackles $CLLS' clinical hold and what it means for #biotech #stocks working on allogeneic CAR-T drugs. Featuring commentary by @bradloncar. Psst... have you followed Mike, yet? He's soon to be your go-to guy for IBD biotech news. https://t.co/BZ632m4tE9